Enhanced in vivo Magnetic Resonance Imaging of Tumors by PEGylated Iron-Oxide-Gold Core-Shell Nanoparticles with Prolonged Blood Circulation Properties

Michiaki Kumagai; Tridib Kumar Sarma; Horacio Cabral; Sachiko Kaida; Masaki Sekino; Nicholas Herlambang; Kensuke Osada; Mitsunobu R Kano; Nobuhiro Nishiyama; Kazunori Kataoka

doi:10.1002/marc.201000341

Enhanced in vivo Magnetic Resonance Imaging of Tumors by PEGylated Iron-Oxide-Gold Core-Shell Nanoparticles with Prolonged Blood Circulation Properties

Macromol Rapid Commun. 2010 Sep 1;31(17):1521-8. doi: 10.1002/marc.201000341.

Authors

Michiaki Kumagai¹, Tridib Kumar Sarma, Horacio Cabral, Sachiko Kaida, Masaki Sekino, Nicholas Herlambang, Kensuke Osada, Mitsunobu R Kano, Nobuhiro Nishiyama, Kazunori Kataoka

Affiliation

¹ Division of Clinical Biotechnology, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.

PMID: 21567561
DOI: 10.1002/marc.201000341

Abstract

High-density poly(ethylene glycol) (PEG)-coated iron-oxide-gold core-shell nanoparticles (AuIONs) were developed as T(2) -weighted magnetic resonance imaging (MRI) contrast agents for cancer imaging. The PEG-coated iron-oxide-gold core-shell nanoparticles (PEG-AuIONs) were approximately 25 nm in diameter with a narrow distribution. Biodistribution experiments in mice bearing a subcutaneous colon cancer model prepared with C26 murine colon adenocarcinoma cells showed high accumulation of the PEG-AuIONs within the tumor mass and low nonspecific accumulation in the liver and spleen, resulting in high specificity to solid tumors. T(2) -weighted MR images following intravenous injection of PEG-AuIONs showed selective negative enhancement of tumor tissue in an orthotopic pancreatic cancer model prepared with MiaPaCa-2 human pancreatic adenocarcinoma cells. These results indicate that PEG-AuIONs are a promising MRI contrast agent for diagnosis of malignant tumors, including pancreatic cancer.